Carlsmed (NasdaqGS:CARL) 2026 Conference Transcript

Summary of Carlsmed Conference Call Company Overview - Company: Carlsmed - Industry: Medical Device, specifically focused on spine surgery - Founded: 2018 - Public Company Status: Recently went public Core Business and Technology - Carlsmed aims to improve healthcare outcomes and reduce costs in spine surgery by minimizing patient reoperations through a comprehensive technology platform that spans preoperative, intraoperative, and postoperative phases [2][3] - The company has developed the aprevo® Technology Platform, which allows for virtual modeling of patient pathology and creation of personalized surgical plans and devices [6][10] Financial Performance - Q4 Revenue: Over $15 million with a gross margin of 76.5%, representing a year-on-year growth of 61% [3] - Full Year Revenue: $50.5 million in the first year as a public company, an 86% year-on-year growth [3] - 2023 Revenue Guidance: Projected revenue between $70 million and $75.5 million, indicating a growth of 44% at the midpoint [4] Market Opportunity - The U.S. spine surgery market includes approximately 445,000 lumbar procedures and 373,000 cervical procedures annually, totaling over 800,000 addressable procedures [5][6] - Carlsmed has seen a nearly 70% increase in its user base, ending the year with 253 trained surgeon users [4] Clinical Validation and Outcomes - Clinical data published in the Global Spine Journal indicates a 74% reduction in revision rates at the two-year mark for patients undergoing the aprevo personalized surgery compared to traditional methods [7] - The company has received Breakthrough Device Designation from the FDA, which facilitates better reimbursement options for its technologies [13][18] Reimbursement and Adoption - Carlsmed has secured a New Technology Add-on Payment from Medicare, providing over $21,000 in incremental reimbursement for hospitals adopting its cervical technology [18] - The company emphasizes the importance of payer support for technology adoption, which can lead to improved patient outcomes and reduced costs [11][14] Product Innovations - The company has expanded its platform to include cervical surgery, addressing specific challenges such as subsidence in patients with osteoporosis [15][18] - Recent innovations include a personalized cervical plating platform and a bilateral approach for minimally invasive procedures, enhancing the surgical experience and outcomes [20][21] Future Outlook - Carlsmed is focused on expanding its technology within the spine market before considering applications in other medical segments [28] - The company aims to continue its rapid growth trajectory and enhance the adoption of its personalized surgery approach [22] Additional Insights - The company utilizes a hybrid commercial model, leveraging both sales agents and direct teams for customer acquisition and support [4] - The technology allows for a zero-inventory business model, simplifying logistics for hospitals [21] - Carlsmed is aware of ongoing clinical studies involving wearable technology for post-operative recovery, although it is not directly integrating such technology at this time [22]